These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 36309864)

  • 41. Low dose orbital radiotherapy for thyroid eye disease.
    Li Yim JF; Sandinha T; Kerr JM; Ritchie D; Kemp EG
    Orbit; 2011 Dec; 30(6):269-74. PubMed ID: 22132844
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The correlation of the neutrophil-lymphocyte ratio to clinical and imaging parameters in patients with thyroid eye disease.
    Zhang X; Han C; Wang H; Sun X; Dou X; He X; Wu D; Shen S; Zhu D; Zhang X; Bi Y
    Endocr Connect; 2022 Nov; 11(11):. PubMed ID: 36099552
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Adalimumab as steroid-sparing treatment of inflammatory-stage thyroid eye disease.
    Ayabe R; Rootman DB; Hwang CJ; Ben-Artzi A; Goldberg R
    Ophthalmic Plast Reconstr Surg; 2014; 30(5):415-9. PubMed ID: 24978425
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A survey of current practices by the British Oculoplastic Surgery Society (BOPSS) and recommendations for delivering a sustainable multidisciplinary approach to thyroid eye disease in the United Kingdom.
    Lee V; Avari P; Williams B; Perros P; Dayan C;
    Eye (Lond); 2020 Sep; 34(9):1662-1671. PubMed ID: 31836832
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Age-Related Changes in the Clinical Phenotype of Compressive Optic Neuropathy in Thyroid Eye Disease.
    Campbell AA; Nanda T; Oropesa S; Kazim M
    Ophthalmic Plast Reconstr Surg; 2019; 35(3):238-242. PubMed ID: 30234838
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Treatment of Graves' disease in patients with thyroid eye disease].
    Sviridenko NY; Sheremeta MS; Belovalova IM; Melnichenko GA
    Vestn Oftalmol; 2021; 137(6):128-135. PubMed ID: 34965078
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Implementation of thyroid eye disease registry in Iran: rationale and research protocol.
    Akbarian S; Sheikhtaheri A; Khorrami F; Ghahvechian H; Karimi N; Kashkouli MB
    Orphanet J Rare Dis; 2024 Feb; 19(1):42. PubMed ID: 38321499
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Sight-threatening Graves' orbitopathy: Twenty years' experience of a multidisciplinary thyroid-eye outpatient clinic.
    Tramunt B; Imbert P; Grunenwald S; Boutault F; Caron P
    Clin Endocrinol (Oxf); 2019 Jan; 90(1):208-213. PubMed ID: 30339291
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [The influence factors of quality-of-life in patients with thyroid-associated ophthalmopathy].
    Shen L; Zhu H; Li XX; Liu DD; Chen XY; Liu H
    Zhonghua Yan Ke Za Zhi; 2017 Aug; 53(8):575-582. PubMed ID: 28851197
    [No Abstract]   [Full Text] [Related]  

  • 50. Tear inflammatory cytokines and ocular surface changes in patients with active thyroid eye disease treated with high-dose intravenous glucocorticoids.
    Xu N; Cui Y; Fu D; Sun F
    J Endocrinol Invest; 2020 Jul; 43(7):901-910. PubMed ID: 31927748
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Combination Model of Thyrotrophin Receptor Antibody and Volumetric Orbital Apex Crowding Index as an Indicator of Dysthyroid Optic Neuropathy.
    Deng Z; Chen L; Tan J; Wang S; Liu D; Wang J; Jiang C; Yang J; Xu B
    Dis Markers; 2021; 2021():9964232. PubMed ID: 34113406
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Teprotumumab for chronic thyroid eye disease.
    Ozzello DJ; Dallalzadeh LO; Liu CY
    Orbit; 2022 Oct; 41(5):539-546. PubMed ID: 34060414
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Surgical rehabilitation of patients with thyroid eye disease: systematic approach].
    Avetisov SE; Grusha YO; Ismailova DS; Kochetkov PA; Danilov SS; Sviridenko NY
    Vestn Oftalmol; 2017; 133(1):4-10. PubMed ID: 28291193
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Hyperthyroid vs hypothyroid eye disease: the same severity and activity.
    Kashkouli MB; Pakdel F; Kiavash V; Heidari I; Heirati A; Jam S
    Eye (Lond); 2011 Nov; 25(11):1442-6. PubMed ID: 21818129
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Elevated Immunoglobulin G4 Levels in Patients with Thyroid Eye Disease and Their Clinical Implications.
    Ye H; Xiao W; Chen R; Zhang P; Tang L; Chen J; Zhang T; Ji X; Shi L; Yang H
    Invest Ophthalmol Vis Sci; 2020 May; 61(5):57. PubMed ID: 32460318
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Serum Vitamin D Deficiency Is an Independent Risk Factor for Thyroid Eye Disease.
    Heisel CJ; Riddering AL; Andrews CA; Kahana A
    Ophthalmic Plast Reconstr Surg; 2020; 36(1):17-20. PubMed ID: 31568022
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Socioeconomic Disparities in the Presentation and Treatment of Graves' Disease and Thyroid Eye Disease.
    Vargason CW; Chelnis JG; Barahimi BI; Mawn LA
    Semin Ophthalmol; 2016; 31(4):409-14. PubMed ID: 27385363
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Conservative Management of Thyroid Eye Disease.
    Khan SH; Malik U; Ahmed F; Siddiqui ZK; Munir S; Rashid N
    J Coll Physicians Surg Pak; 2021 May; 31(5):599-601. PubMed ID: 34027879
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Teprotumumab: Interpreting the Clinical Trials in the Context of Thyroid Eye Disease Pathogenesis and Current Therapies.
    Winn BJ; Kersten RC
    Ophthalmology; 2021 Nov; 128(11):1627-1651. PubMed ID: 33930408
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Objective and subjective outcomes of strabismus surgery in Graves' orbitopathy: a prospective multicentre study.
    Jellema HM; Saeed P; Mombaerts I; Dolman PJ; Garrity J; Kazim M; Dhrami-Gavazi E; Lyons C; Nieuwkerk P; Mourits MP
    Acta Ophthalmol; 2017 Jun; 95(4):386-391. PubMed ID: 28133945
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.